T cells number and function in young asthmatic children during 2 years treatment with inhaled budesonide. 1994

B Volovitz, and B Shohat, and J Amir, and M Nussinovitch, and I Varsano
Department of Pediatrics, Children's Medical Centre of Israel, Petah Tikva.

Corticosteroids are known to affect the number and function of circulating lymphocytes in humans. The effect of 2 years administration of inhaled budesonide (200 micrograms/day) on the number and function of B and T lymphocytes and T cell subsets was evaluated in 16 young children with severe asthma. The number of T and B cells and T suppressor/cytotoxic cells (CD8 T cell) and T helper/inducer cells (CD4 T cell) before therapy was found to be comparable to the number of cells observed in the healthy control group. Two years administration of inhaled budesonide did not significantly alter the percentage and absolute number of all these cells. The functional activity of T lymphocytes was evaluated by the "local xenogeneic graft versus host reaction" (GVHR). A positive (normal) GVHR was observed in only 5 of the 16 children (31%) in the budesonide group before therapy, compared to 15 of 16 children (94%) in the healthy control group. During the 2 years treatment with inhaled budesonide, the percentage of patients having positive GVHR increased from 31% before therapy to 69% and 77% after 1 and 2 years of therapy (P = 0.05 and 0.02), respectively. The data observed in this study indicate that 2 years administration of inhaled budesonide did not alter the number of B and T lymphocytes and T cell subsets. However, it was associated with improvement in the GVHR function of T cells.

UI MeSH Term Description Entries
D008297 Male Males
D011282 Pregnenediones Unsaturated pregnane derivatives containing two keto groups on side chains or ring structures. Diketopregnenes,Dioxopregnenes
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D005938 Glucocorticoids A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations

Related Publications

B Volovitz, and B Shohat, and J Amir, and M Nussinovitch, and I Varsano
February 1991, Acta paediatrica Scandinavica,
B Volovitz, and B Shohat, and J Amir, and M Nussinovitch, and I Varsano
March 2017, Basic & clinical pharmacology & toxicology,
B Volovitz, and B Shohat, and J Amir, and M Nussinovitch, and I Varsano
January 1997, The Pediatric infectious disease journal,
B Volovitz, and B Shohat, and J Amir, and M Nussinovitch, and I Varsano
December 1993, Pediatric pulmonology,
B Volovitz, and B Shohat, and J Amir, and M Nussinovitch, and I Varsano
January 1999, Salud publica de Mexico,
B Volovitz, and B Shohat, and J Amir, and M Nussinovitch, and I Varsano
November 1997, The European respiratory journal,
B Volovitz, and B Shohat, and J Amir, and M Nussinovitch, and I Varsano
July 1991, BMJ (Clinical research ed.),
B Volovitz, and B Shohat, and J Amir, and M Nussinovitch, and I Varsano
December 1995, The Journal of allergy and clinical immunology,
B Volovitz, and B Shohat, and J Amir, and M Nussinovitch, and I Varsano
May 1990, The British journal of clinical practice,
B Volovitz, and B Shohat, and J Amir, and M Nussinovitch, and I Varsano
February 2006, The European respiratory journal,
Copied contents to your clipboard!